Research articles
ScienceAsia 48 (2022):ID 769-775 |doi:
10.2306/scienceasia1513-1874.2022.119
VASH2 promotes oxaliplatin resistance in gastric cancer cells
via the AKT signaling pathway
Baoli Lin, Zhi Chen*
ABSTRACT: Gastric cancer (GC) is one of the most common malignant tumors worldwide. GC cells are sensitive
to chemotherapy drugs such as oxaliplatin (OHP, trans -/- diaminocyclohexane oxaliplatin or L-OHP). The molecular
mechanisms involved in regulation of L-OHP resistance remain unknown. Vasohibin 2 (VASH2), a member of the
vasohibin (VASH) family, has been implicated in chemical resistance in several cancer types. However, the possible role
of VASH2 in the oxaliplatin resistance of GC is still unclear. In this study, we constructed two L-OHP resistance GC cell
lines and found that VASH2 was highly expressed in L-OHP-treated GC cells. Downregulation of VASH2 suppressed the
viability of L-OHP-treated GC cells. In addition, VASH2 knockdown stimulated the apoptosis of two oxaliplatin-resistant
GC cell lines. In conclusion, our results suggested that VASH2 promoted oxaliplatin resistance in GC cells through the
serthreonine protein kinase AKT pathway.
Download PDF
43 Downloads 1265 Views
a |
Department of Pharmacy, Wenzhou Central Hospital, Wenzhou, Zhejiang 325000 China |
* Corresponding author, E-mail: chenzhi11213@163.com
Received 20 Dec 2021, Accepted 30 May 2022
|